ÂÜÀòÂÒÂ×

Roy joined OrbiMed in 2016 and specializes in biotechnology investments in both private and public companies and is also involved with the formation and investment in early-stage companies. Prior to joining OrbiMed, Roy was a Director of Mergers, Acquisitions and Licensing at Bayer Health Care where he was responsible for Health Care transactions. While at Bayer, Roy held several positions of increasing responsibilities in Oncology Marketing and in Business Development.

Roy received his B.A. in Chemistry and Biology from Tel Aviv University and M.Sc. and Ph.D. in Molecular Genetics from the Weizmann Institute in Israel and an MBA in Finance and Healthcare Management from the Wharton School of the University of Pennsylvania.